Inge Van de Walle
Company: Argenx
Job title: asset lead
Seminars:
Empasiburbart for MMN: Clinical Update & Biomarker Strategy 4:30 pm
Outlining a comprehensive clinical update on Empasiprubart’s performance in treating MMN, including key efficacy data, patient outcomes, and safety profile from ongoing trials Detailing the specific biomarker strategy employed in Empasiprubart trials for MMN, highlighting how these markers are used to assess disease activity, predict treatment response, and monitor therapeutic impact Exploring the implications of…Read more
day: Conference Day One